August 7, 2025 — Leads & Copy — Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a biotechnology company focused on cell therapy for autoimmune diseases, has reported its financial results for the second quarter ended June 30, 2025, and provided an update on its corporate activities.
The company’s cash, cash equivalents, and restricted cash totaled approximately $162.1 million as of June 30, 2025, which is expected to support planned operations into mid-2027, including the completion of the ongoing Phase 3 AURORA trial.
The Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) has been initiated, and preliminary data from the Phase 2 trial of Descartes-08 in systemic lupus erythematosus is expected in the second half of 2025. Additionally, the initiation of a Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications is also expected in the second half of 2025.
Research and development expenses for the second quarter of 2025 were $14.9 million, compared to $12.7 million for the same period in 2024. General and administrative expenses were $7.2 million, compared to $7.0 million for the same period in 2024. Net income for the quarter was $15.9 million, or $0.51 net income per share.
Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian, said the company has entered the second half of the year with momentum and is focused on advancing its mission to deliver transformative cell therapies to patients with autoimmune diseases.
Descartes-08 is Cartesian’s lead cell therapy candidate, an autologous CAR-T product targeting B-cell maturation antigen (BCMA) in clinical development for generalized myasthenia gravis (MG) and systemic lupus erythematosus. Descartes-15 is a next-generation, autologous anti-BCMA CAR-T cell therapy. A Phase 1 dose escalation trial of Descartes-15 is underway to assess the safety and tolerability of outpatient administration in patients with multiple myeloma.
Investor Contact:
Megan LeDuc
Associate Director of Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
Source: Cartesian Therapeutics, Inc.
